VINH PHUC PHARMACEUTICAL JOINT - STOCK COMPANY

vinphaco.vn

With motto "for public health"​, the medical ethics of the physician in who produce as well as in business to defend the interest people the client Everlasting Lucky materia medica joint stock company (have VINPHACO business name) always exaltted is motto what VINPHACO always tend.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Medical

SOTIRA ANNOUNCES THE SUCCESSFUL COMPLETION OF SECOND PHASE OF PRE-CLINICAL TESTING FOR COVID-19 THERAPEUTIC AND VACCINE-ALTERNATIVE

Sotira | November 25, 2020

news image

Sotira, the Phoenix based biotech organization, is pleased to report the successful finish of the second period of pre-clinical testing for its COVID-19 therapeutic and vaccine-alternative, KEPTIDE™ COVID, confirming that this cutting-edge molecular therapy completely prevented of SARS-CoV2 in the lungs and kidney. These mice are viewed as a best quality level preclinical model to study COVID-19 on the grounds that the mice express human ACE2, the receptor utilized by the virus to gain ent...

Read More

SEVERITY OF COVID-19 MAY DEPEND ON YOUR INDIVIDUAL GENETIC VARIATION IN IMMUNE SYSTEM

SciTechDaily | April 19, 2020

news image

Genetic variability in the human immune system may affect susceptibility to, and severity of infection by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus responsible for the coronavirus disease (COVID-19). The research is published on April 17, 2020, in the Journal of Virology, a publication of the American Society for Microbiology. Individual genetic variation may explain differences in the strength of immune responses. Certain immune system genes, called human leukocyte...

Read More

Research

CEDILLA THERAPEUTICS EXPANDS LEADERSHIP TEAM WITH KEY APPOINTMENTS ACROSS R&D AND FINANCE

Cedilla Therapeutics | November 17, 2021

news image

Cedilla Therapeutics, a biotechnology company bringing a new dimension to precision oncology, announced appointments across its research and development (R&D) and finance teams, including Joshua Murtie, Ph.D., as Vice President of Biology and Chris Lindblom as Vice President of Finance. These hires are part of an ongoing initiative to expand Cedilla’s leadership and enable future growth as the company progresses its lead programs, conditional inhibitors of TEAD and CDK2, toward the cli...

Read More

Industrial Impact

ADAPTIVE BIOTECHNOLOGIES ANNOUNCES NEW DATA DEMONSTRATING IMMUNOSEQ® TECHNOLOGY CAN IDENTIFY T-CELL RECEPTORS ASSOCIATED WITH CROHN’S DISEASE

Adaptive Biotechnologies | February 19, 2022

news image

Adaptive Biotechnologies Corporation a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, presented data on T-cell receptor (TCR) sequences associated with Crohn’s disease (CD) during an oral presentation today at the 17th Congress of European Crohn’s and Colitis Organisation (ECCO) being held virtually February 16-19. The study identified and characterized TCR sequences associ...

Read More
news image

Medical

SOTIRA ANNOUNCES THE SUCCESSFUL COMPLETION OF SECOND PHASE OF PRE-CLINICAL TESTING FOR COVID-19 THERAPEUTIC AND VACCINE-ALTERNATIVE

Sotira | November 25, 2020

Sotira, the Phoenix based biotech organization, is pleased to report the successful finish of the second period of pre-clinical testing for its COVID-19 therapeutic and vaccine-alternative, KEPTIDE™ COVID, confirming that this cutting-edge molecular therapy completely prevented of SARS-CoV2 in the lungs and kidney. These mice are viewed as a best quality level preclinical model to study COVID-19 on the grounds that the mice express human ACE2, the receptor utilized by the virus to gain ent...

Read More
news image

SEVERITY OF COVID-19 MAY DEPEND ON YOUR INDIVIDUAL GENETIC VARIATION IN IMMUNE SYSTEM

SciTechDaily | April 19, 2020

Genetic variability in the human immune system may affect susceptibility to, and severity of infection by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus responsible for the coronavirus disease (COVID-19). The research is published on April 17, 2020, in the Journal of Virology, a publication of the American Society for Microbiology. Individual genetic variation may explain differences in the strength of immune responses. Certain immune system genes, called human leukocyte...

Read More
news image

Research

CEDILLA THERAPEUTICS EXPANDS LEADERSHIP TEAM WITH KEY APPOINTMENTS ACROSS R&D AND FINANCE

Cedilla Therapeutics | November 17, 2021

Cedilla Therapeutics, a biotechnology company bringing a new dimension to precision oncology, announced appointments across its research and development (R&D) and finance teams, including Joshua Murtie, Ph.D., as Vice President of Biology and Chris Lindblom as Vice President of Finance. These hires are part of an ongoing initiative to expand Cedilla’s leadership and enable future growth as the company progresses its lead programs, conditional inhibitors of TEAD and CDK2, toward the cli...

Read More
news image

Industrial Impact

ADAPTIVE BIOTECHNOLOGIES ANNOUNCES NEW DATA DEMONSTRATING IMMUNOSEQ® TECHNOLOGY CAN IDENTIFY T-CELL RECEPTORS ASSOCIATED WITH CROHN’S DISEASE

Adaptive Biotechnologies | February 19, 2022

Adaptive Biotechnologies Corporation a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, presented data on T-cell receptor (TCR) sequences associated with Crohn’s disease (CD) during an oral presentation today at the 17th Congress of European Crohn’s and Colitis Organisation (ECCO) being held virtually February 16-19. The study identified and characterized TCR sequences associ...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us